Dec 4 2009
RemedyMD (www.RemedyMD.com), the leading provider of Disease Registry software, today announced the first nationwide Pediatric Diabetes Registry. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.
Details about the registry:
http://www.remedymd.com/cer100/pediatric_diabetes.html
RemedyMD’s pediatric diabetes registry tracks patient outcomes over time including changes in HgA1c, LDL cholesterol and insulin levels. Researchers and clinicians can also track HgA1c by medication or medication class and easily generate reports showing results by multiple demographic or clinical indicators such as:
- Age
- Gender
- Ethnicity
- Insurance type
The new registry contains 1,500+ pediatric diabetes-specific fields for physicians, nurses, social workers, and dietitians to support all elements of pediatric diabetes research. Additionally, the registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.
“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies,” said Gary D. Kennedy, Founder and CEO of RemedyMD.
RemedyMD’s new pediatric diabetes registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to pediatric diabetes research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.
In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of pediatric diabetes researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/pediatric_diabetes.html.